Table 1.

The spectrum of mucocutaneous manifestations of SARS-CoV-2 infection

Clinical findings	No. of patients	Author	Country	Refs.
Rash	2 / 1099	Guan et al.	China	[37]
	14/88	Recalcati et al.	Italy	[81]
	2 / 103	Hedou et al.	France	[41]
	1 case report	Mahé et al.	France	[70]
	1 case report	Joob et al.	Thailand	[52]
	1 case report	Hunt et al.	United States	[47]
	1 case report	Amatore et al.	France	[4]
	1 case report	Zengarini et al.	Italy	[118]
	1 case report	Avellana-Moreno et al.	Spain	[6]
	1 / 3	Sachdeva et al.	Italy	[84]
	2 / 2	Macedo-Pérez et al.	Mexico	[68]
Vesicular lesions	9% / 375	Galván-Casas et al.	Spain	[32]
	1 / 88	Recalcati et al.	Italy	[81]
	3 / 130	Tammaro et al.	Italy / Barcelona	[96]
	1 / 3	Sachdeva et al.	Italy	[84]
Urticarial lesions	19% / 375	Galván-Casas et al.	Spain	[32]
	3 / 88	Recalcati et al.	Italy	[81]
	2 / 103	Hedou et al.	France	[41]
	1 case report	Henry et al.	France	[42]
	2 / 2	Van Damme et al.	Belgium	[103]
	1 case report	Gunawan et al.	Indonesia	[38]
	1 case report	Falkenhain-López et al.	Spain	[27]
Chilblains	1 case report	Alramthan et al.	Kuwait	[2]
	19% / 375	Galván-Casas et al.	Spain	[32]
	1 / 14	Bouaziz et al.	France	[12]
Livedo reticularis	1 case report	Manalo et al.	United States	[71]
	1 / 14	Bouaziz et al.	France	[12]
Acral cyanosis/dry gangrene/necrotic purpura	7 / 7	Zhang et al.	China	[120]
	3 / 3	Suarez-Valle et al.	Spain	[94]
	1 / 14	Bouaziz et al.	France	[12]

Other cutaneous manifestations reported in COVID-19 patients include maculopapular lesions resembling pityriasis rosea, erythema elevatum diutinum, erythema multiforme, Grover disease, cutaneous vasculitis, and elbow/knee joint erythematous-edematous plaques [16, 22, 25, 32, 49, 83, 84]